INTRODUCTION
Choroidal metastasis occurs in 7-11% of patients with breast carcinomas (1) . Treatment includes external beam radiation therapy, tamoxifen, aromatase inhibitors (letrozole) and chemotherapy, including systemic bevacizumab (1) (2) (3) . Bevacizumab, a monoclonal antibody, is anti-angiogenetic, thereby limiting tumour vascularization and growth. It has been approved for systemic use in colon carcinomas (4) . Its "off label" use in ophthalmology has evolved from the treatment of age-related macular degeneration (ARMD) to proliferative diabetic retinopathy (PDR) and macula oedema (5) (6) (7) (8) . Bevacizumab is also an anti-vascular endothelial growth factor (VEGF) agent which reduces permeability and allows resorption of subretinal fluid. Her best corrected visual acuity was 20/50 in the right eye and she could only visualize hand motions in the left eye. The left eye was amblyopic, with poor vision from birth and she had an esotropia (convergent squint) and a white cataract obscuring the fundal view. The right eye had a large 'creamish' elevated choroidal mass with neurosensory detachment, 6 disc diameters in diameter in the macula and also superior to the disc (Fig. 1a) . She refused chemotherapy, but wanted visual improvement in her only functioning eye (right eye). She underwent right intravitreal bevacizumab injection (1.25 mg in 0.05 ml). The choroidal mass reduced in four weeks (Figs. 1b, 2b) . At the six-week review, her vision had improved to 20/20 in the right eye, and the choroidal metastasis in the posterior pole had resolved (Fig. 1c) . Repeat OCT scan showed significant reduction in the foveal thickness to almost normal thickness [256 µm] (Fig. 2c) .
DISCUSSION
Bevacizumab, an anti-angiogenic agent, reduces vascular permeability when used intravitreally. The "off label" use of bevacizumab has increased over the past decade with evolving uses and varying concentrations for intraocular use. Amselem et al used 4 mg (0.16 ml) of bevacizumab intravitreally to treat choroidal metastases from breast carcinoma and noted visual improvement from 20/100 to 20/60 in three weeks (9). Yao et al used adjuvant bevacizumab 2.5 mg (0.1 ml) post chemotherapy with improvement from 20/400 to 20/30 at six months (10) . The index case had significant improvement with a non-adjuvant (no previous systemic chemotherapy), single intravitreal bevacizumab injection at a lower dosage (1.25 mg/0.05 ml). This shows that intraocular use can be effective on metastasis at a very low dosage and volume (0.05 ml).
Early treatment before significant exudation and tumour growth may yield good results, possibly due to less chronic destruction of the choroid and inner retinal layer. Monitoring with the high definition OCT is important in the management. Low dose and low volume intravitreal (intraocular) bevacizumab injection is safe and effective in treating choroidal metastasis from breast carcinoma. It also reduces the risk of systemic chemotherapy complications, especially in a patient with only one functioning eye, as in this case, and who achieved return of normal vision within a few weeks of treatment.
Bevacizumab for Choroidal Metastases 
